# Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine For The Treatment Of Uncomplicated, Symptomatic Falciparum Malaria In Southeast Asia

> **NCT00084240** · PHASE2,PHASE3 · TERMINATED · sponsor: **Pfizer** · enrollment: 32 (actual)

## Conditions studied

- Malaria, Falciparum

## Interventions

- **DRUG:** Azithromycin/Chloroquine
- **DRUG:** Sulfadoxine-Pyrimethamine/Chloroquine

## Key facts

- **NCT ID:** NCT00084240
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-03
- **Primary completion:** —
- **Final completion:** 2005-04
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** See Detailed Description
- **Last updated:** 2008-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00084240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00084240, "Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine For The Treatment Of Uncomplicated, Symptomatic Falciparum Malaria In Southeast Asia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00084240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*